Despite a wave of new therapies reshaping treatment across rare and glomerular kidney diseases, Alport syndrome has largely been left behind. Among kidney diseases evaluated by Spherix Global Insights ...
In this video from GlomCon Hawaii, Dana Rizk, MD, discusses highlights from a presentation concerning the design and ...
In this video from GlomCon Hawaii, Dana Rizk, MD, discusses the results of a phase 3 clinical trial concerning the safety and efficacy of sibeprenlimab-szsi in the treatment of immunoglobulin A ...
智通财经APP获悉，8月26日，礼邦医药(09637)上市后首份中期业绩交出亮眼答卷：收入规模增至去年同期的8.6倍。更值得关注的是，这份成绩单恰逢全球肾病创新药加速商业化、优质资产持续获得资本重估，礼邦所代表的中国垂直专科Biopharma路径也由 ...
The Trump administration looks set to unveil a new slate of most favored nation (MFN) drug pricing deals with several ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
8月25日晚间，苏州信诺维医药科技股份有限公司（以下简称“信诺维”）披露首次公开发行股票并在科创板上市招股意向书、发行安排及初步询价公告等，启动科创板发行工作。 信诺维主要聚焦抗肿瘤、抗感染等领域，目前已形成“1+3+N”的创新药管线梯队，即1个产品处于药品上市许可申请受理阶段，3个产品处于临床Ⅲ期或关键性临床研究阶段，另有多个早期研发管线持续推进。 在抗感染领域，信诺维研发的注射用亚胺西福NDA ...
MovieZine Norge on MSN
Svensk krimhelt vender tilbake! Nå starter innspillingen av flere nye «Johan Falk»-filmer
En av Sveriges mest populære politifigurer er tilbake med tre nye filmer. Den første har premiere i 2027. Dette er øyeblikket ...
Cytokinetics booked its first full quarter of MYQORZO sales on Aug. 6. Armistice Capital used the same three months to raise ...
针对抗感染领域，信诺维研发的注射用亚胺西福药品上市许可申请（NDA）已于2025年7月获得受理，预计于2026年获批上市。该药物为β-内酰胺酶抑制剂，抗菌谱广，可有效覆盖三大碳青霉烯耐药革兰阴性菌。针对抗肿瘤领域，公司研发的XNW5004、XNW27 ...
미국 트럼프 행정부가 대형 제약사에 이어 중견 제약·바이오 기업들과 새로운 최혜국 대우(Most Favored Nation, MFN) 의약품 가격 협약을 추진한다. 28일 한국바이오협회 바이오경제연구센터 이슈브리핑에 따르면, ...
招股意向书显示，信诺维聚焦抗肿瘤、抗感染等重大疾病领域，搭建起“1+3+N”的创新药管线梯队，即1个产品处于NDA受理阶段，3个产品处于临床III期，另有多个早期管线处于稳步有序推进中。
Some results have been hidden because they may be inaccessible to you
Show inaccessible results